Loading clinical trials...

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy | Clinical Trials | Clareo Health

RECRUITINGNA

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

NCT03514368•Institut Claudius Regaud

View on ClinicalTrials.gov

Summary

This is a translational, open-label, multi-site, prospective cohort study aiming to identify and to monitor immunological biomarkers associated with therapeutic response to immune checkpoints blockade (ICB), in patients with multiple types of advanced (unresectable and/or metastatic) solid cancers. The study will be conducted on a population of patients receiving ICB (anti-PD-1 or anti-PD-L1 or anti-CTLA4, alone or in combination) in the context of either routine care or a clinical study protocol. Patients with any of the following tumor types may be enrolled in the trial: * Non-Small Cell Lung Cancer (NSCLC), * Head and neck cancer, * Melanoma, * Bladder cancer, * Other tumor types when Immuno-Oncology agent is expected to be efficient or when a clinical trial is an option. For each included patient, tumor biopsy specimens and blood samples will be collected at different time points. All included patients will be followed-up until progression. After this date, survival data will be collected.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years at the time of study entry.
•2. Patient with histologically documented metastatic and/or unresectable solid malignant tumor (NSCLC, head and neck, melanoma (except uveal melanoma), bladder cancer or any other advanced solid tumor when I-O agent is expected to be efficient or when a clinical trial is an option).
•3. Patient for which a treatment with immune checkpoint blockade including, but not limited to, anti-PD-1, anti-PD-L1 and anti-CTLA-4 mAb alone or in combination has been decided.
•4. Archived tumor specimen available or feasible for pre-treatment tumor biopsy.
•5. Current treatment with ICB not yet started.
•6. Evaluable disease (measurable as per RECIST 1.1. or not).
•7. ECOG Performance status 0-2.
•8. Patient able to participate and willing to give informed consent prior to performance of any study-related procedures.
•9. Patient affiliated to a Social Health Insurance in France.

Exclusion Criteria

•1. Patient pregnant, or breast-feeding.
•2. Uveal melanoma
•3. Any condition contraindicated with tumor /blood sampling procedures required by the protocol.
•4. Known history of positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
•5. Any current severe or uncontrolled disease, including, but not limited to ongoing or active infection and auto immune disorders.
•6. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
•7. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Locations (3)

Hopital Larrey

Toulouse, France

Institut Universitaire Du Cancer de Toulouse - Oncopole

Toulouse, France

Chu Rangueil

Toulouse, France

Key Dates

Start Date

May 28, 2018

Primary Completion Date

November 1, 2029

Completion Date

November 1, 2029

Last Updated

February 19, 2026

Enrollment

770

ESTIMATED participants

Conditions

Solid Cancers

Interventions

Patients treated with immune checkpoint blockade

OTHER

Contacts

Jean-Pierre DELORD, MD

CONTACT

05 31 15 55 00 delord.jean-pierre@iuct-oncopole.fr

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842

Advanced Solid Cancers

View study

RECRUITINGPHASE1/PHASE2

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

NCT07371663

Solid CancersNSCLC (Advanced Non-small Cell Lung Cancer)+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 19, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

Real-life Performance Evaluation of the LiFlow X-ray Platform

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway